An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies
Status:
Completed
Trial end date:
2017-06-26
Target enrollment:
Participant gender:
Summary
This open-label, extension study is designed to provide continuing treatment with RO5045337
to participants who have completed parent studies NO21279 (NCT00623870), NO21280
(NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
Participants are eligible to participate in this study if they have completed required Phase
1 study assessments for primary objectives of respective parent protocol and are having
evidence of clinical benefit (as defined by the parent protocol). Participants will continue
the most similar dose and formulation available (which does not exceed the maximum tolerated
dose [MTD] or the maximum safely administered dose for that formulation during Phase 1) and
the same schedule of RO5045337 treatment that they were receiving at the time of
transitioning from the parent clinical study protocol.